13th Nov 2014 07:44
LONDON (Alliance News) - AstraZeneca PLC said Thursday it has launched a pre-clinical development programme to evaluate its investigation antibody MEDI2452 as a reversal agent for its compound Brilinta in rare emergency situations.
The company said that in certain emergency situations, doctors need to be able to swiftly reverse the effects of oral antiplatelet agents to enable emergency surgery, or quickly respond to a major bleeding event. Currently, there are no US Food and Drug Administration approved medications to counteract the antiplatelet effect, AstraZeneca said.
"If the circumstances demand it, we believe MEDI2452 has the potential to help address this need for patients treated with Brilinta," said Marc Ditmarsch, the global development lead for Brilinta, in a statement.
The initiation of the development programme comes ahead of the AHA Scientific Sessions event in Chicago starting this weekend, at which AstraZeneca will present nine abstracts across its pipeline and marketed products.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca